Mounjaro®
Starting from £179.99/mo
Start journey Learn moreExcessive burping on Wegovy is one of the most commonly reported gastrointestinal side effects of semaglutide. Clinical trial data shows that GI symptoms affected a significant proportion of participants, with belching and indigestion appearing alongside nausea as top complaints in the early weeks of treatment. Wegovy works partly by slowing how quickly food leaves your stomach — and that delayed gastric emptying is the direct reason gas builds up and needs somewhere to go. It is a prescription-only medicine, so any changes to how you're managing side effects should be discussed with the prescriber who oversees your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity and tracked them over 68 weeks on semaglutide 2.4mg. Gastrointestinal events were the most frequently reported side effects throughout, and the GI burden was highest in the first weeks after each dose increase. Belching and dyspepsia (indigestion) featured consistently in that picture, and if you want a closer look at what to expect at a specific stage, the full breakdown of side effects of Wegovy 1.0 shows how the symptom profile typically looks at that early dose. The underlying reason is well understood: semaglutide activates GLP-1 receptors in the gut and brain, which reduces appetite and (crucially for burping) slows the rate at which the stomach empties into the small intestine.
When food sits in the stomach longer than it ordinarily would, gas produced during digestion has more time to accumulate. Some of that gas escapes upward as belching; some travels downward. Neither is a sign that anything has gone wrong. The NHS medicines page for semaglutide lists burping explicitly among the common side effects of Wegovy, confirming it affects at least one in ten people, and our dedicated page on whether burping is a side effect of Wegovy explains in more detail why the real-world frequency is probably higher than that figure suggests. That figure likely underrepresents the real-world frequency, since many people simply manage the symptom without reporting it.
Dose increases tend to restart or worsen the symptom temporarily. If you have just moved to a new pen strength and the belching has picked up again, that timing is not a coincidence. The standard titration schedule steps up roughly every four weeks, so the adjustment windows repeat; most people find each one slightly easier than the last.
Certain everyday habits dramatically amplify the gas build-up that slow gastric emptying already encourages. Eating quickly is probably the biggest culprit: when you eat fast, you swallow air with every mouthful, and on Wegovy that air has nowhere to go quickly because the stomach is emptying slowly. Fizzy drinks add gas directly. Chewing gum, drinking through a straw, and talking while eating all contribute to aerophagia, the technical term for swallowing excess air.
High-fat meals are worth mentioning separately. Fat already slows gastric emptying under normal circumstances; combined with semaglutide's effect, a heavy meal can leave the stomach feeling very full and gassy for several hours. Some people find that the foods they previously tolerated well (a creamy pasta, a fried breakfast) now reliably trigger belching for the rest of the morning, and our page on Wegovy burping looks at exactly these dietary patterns and why certain meals seem to set it off more than others.
Eating position matters too. Lying down shortly after a meal gives gas less chance to travel in the right direction. A short upright period after eating, even just sitting at a table rather than moving to the sofa, can make a noticeable difference. For more practical day-to-day strategies, the guidance on managing burping while on Wegovy goes into further detail on meal pacing and dietary adjustments.
Burping on its own, in the first weeks of treatment or after a dose increase, is almost always part of the expected GI adjustment. It becomes worth reporting to your prescriber when it appears together with other signs. Severe, persistent upper-abdominal pain that radiates to the back is the combination that warrants urgent medical assessment: the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and that symptom pattern is the key warning sign.
Gallbladder-related symptoms (pain in the upper right abdomen, especially after eating fatty food) can also present alongside bloating and belching and are separately listed as a known risk with semaglutide. Persistent nausea and vomiting severe enough to stop you eating or drinking properly can lead to dehydration; that too needs clinical attention rather than waiting it out at home. If you are ever uncertain, the team at nume's support line is available seven days a week, and for urgent symptoms NHS 111 is always the right first call. You can also report any suspected side effects directly to the MHRA via the Yellow Card scheme.
The wider picture of how semaglutide behaves in the body (including the full side-effect profile across all dose levels) is covered on the Wegovy side effects page, which sets individual symptoms in their clinical context.
A question our prescribers hear fairly regularly is whether persistent belching means the dose should be slowed down or paused. The honest answer is: sometimes. If GI symptoms are severe enough to affect daily life, a prescriber may recommend staying at the current dose for longer before increasing, rather than following the standard four-week titration. That is a clinical decision based on your full picture, not something to navigate alone.
It helps to keep a rough note of when the burping is worst, whether it correlates with specific foods, a time of day, or the days immediately after your weekly injection. That information gives a prescriber something concrete to work with. For patients who find side effects cluster in the day or two after each weekly dose, some find that timing their injection on a Friday (rather than a Monday, when the working week makes symptoms harder to manage) shifts the peak to the weekend. It is a small adjustment, but practical things like that do make a difference.
If you are still deciding whether Wegovy is the right option for you, the Wegovy treatment overview explains how the medicine works, what eligibility looks like, and how private prescribing through a GPhC-registered pharmacy works. And if you are ready to take the next step, our prescribers at the nume clinical team review consultations the same day, a real clinician reads your answers, not an automated system. Check your eligibility to get started.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.